Imunon Valuation
| IMNN Stock | USD 0.83 0.02 2.47% |
Today, the firm appears to be overvalued. Imunon Inc retains a regular Real Value of $0.73 per share. The prevalent price of the firm is $0.83. Our model calculates the value of Imunon Inc from evaluating the firm fundamentals such as Shares Owned By Insiders of 1.09 %, return on asset of -0.67, and Return On Equity of -1.48 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Imunon's valuation include:
Price Book 1.4673 | Enterprise Value 3 M | Enterprise Value Ebitda 0.9097 | Price Sales 17.9405 | Enterprise Value Revenue 4.0043 |
Overvalued
Today
Please note that Imunon's price fluctuation is extremely dangerous at this time. Calculation of the real value of Imunon Inc is based on 3 months time horizon. Increasing Imunon's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Imunon is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Imunon Stock. However, Imunon's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.83 | Real 0.73 | Target 12.5 | Hype 0.83 | Naive 0.9 |
The intrinsic value of Imunon's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Imunon's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Imunon Inc helps investors to forecast how Imunon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Imunon more accurately as focusing exclusively on Imunon's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Imunon's intrinsic value based on its ongoing forecasts of Imunon's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Imunon's closest peers.
Imunon Cash |
|
Imunon Valuation Trend
Knowing Imunon's actual value is paramount for traders when making sound investment determinations. Using both Imunon's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Imunon Total Value Analysis
Imunon Inc is currently estimated to have valuation of 2.97 M with market capitalization of 12.02 M, debt of 1.62 M, and cash on hands of 42.11 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Imunon fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.97 M | 12.02 M | 1.62 M | 42.11 M |
Imunon Investor Information
About 15.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Imunon Inc recorded a loss per share of 1.91. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 1st of March 2022. Based on the analysis of Imunon's profitability, liquidity, and operating efficiency, Imunon Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Imunon Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Imunon has an asset utilization ratio of 0.57 percent. This suggests that the Company is making $0.005703 for each dollar of assets. An increasing asset utilization means that Imunon Inc is more efficient with each dollar of assets it utilizes for everyday operations.Imunon Ownership Allocation
The market capitalization of Imunon is $12.02 Million. Roughly 83.47 (percent) of Imunon outstanding shares are held by general public with 1.09 % owned by insiders and only 15.44 pct. by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Imunon Profitability Analysis
The company reported the previous year's revenue of 125 K. Net Loss for the year was (19.51 M) with profit before overhead, payroll, taxes, and interest of 500 K.About Imunon Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Imunon Inc. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Imunon Inc based exclusively on its fundamental and basic technical indicators. By analyzing Imunon's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Imunon's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Imunon. We calculate exposure to Imunon's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Imunon's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -720 K | -684 K | |
| Pretax Profit Margin | (67.44) | (70.81) | |
| Operating Profit Margin | (44.86) | (47.10) | |
| Net Loss | (64.62) | (67.85) | |
| Gross Profit Margin | (0.53) | (0.56) |
Imunon Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 9 M |
Imunon Current Valuation Indicators
Imunon's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Imunon's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Imunon, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Imunon's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Imunon's worth.When determining whether Imunon Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Imunon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imunon Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imunon Inc Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.014 | Return On Assets (0.67) | Return On Equity (1.48) |
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.